11:26 , Sep 28, 2018 |  BC Extra  |  Preclinical News

Two strategies block immune-mediated metastases in mice

Cold Spring Harbor Laboratory researchers and a team from two Italian institutions have published two different strategies to fight immune-mediated lung metastases. Dormant cancer cells can persist for years before awakening and proliferating, leading to...
00:00 , Aug 11, 2018 |  BioCentury  |  Product Development

Exacerbation management

Based on work spearheaded by the Cystic Fibrosis Foundation, Corbus Pharmaceuticals Holdings Inc. will be the first company to attempt to gain approval in CF based on pulmonary exacerbations instead of FEV1. The company is...
18:53 , Jul 27, 2018 |  BC Week In Review  |  Clinical News

NovaBiotics' oral Lynovex improves outcomes in Phase II for CF

NovaBiotics Ltd. (Aberdeen, U.K.) said oral Lynovex cysteamine (formerly NM001) as an adjunct to standard of care (SOC) significantly improved health-related questionnaire scores and reduced respiratory symptom severity compared with SOC alone in the Phase...
02:53 , Dec 8, 2017 |  BC Week In Review  |  Company News

Mero licenses AAT deficiency candidate from AstraZeneca

AstraZeneca plc (LSE:AZN; NYSE:AZN) granted Mereo BioPharma Group plc (LSE:MPH) an exclusive license and option to acquire AZD9668, an oral inhibitor of neutrophil elastase (ELANE; NE; HLE) which is in development to treat alpha-1 antitrypsin...
21:05 , Nov 9, 2016 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer Patient sample, cell culture and mouse studies suggest inhibiting neutrophil extracellular trap s (NETs) with DNASE1 or other agents could help treat metastatic breast cancer. In primary tumor samples from 20 patients...
07:00 , Sep 5, 2016 |  BC Week In Review  |  Clinical News

Inhaled alpha-1 antitrypsin: Phase II data

Top-line data from a double-blind, U.S. Phase II trial in 36 patients with AAT deficiency showed that once-daily 80 and 160 mg doses of inhaled AAT for 12 weeks each met the co-primary endpoints of...
07:00 , Aug 30, 2016 |  BC Extra  |  Clinical News

Kamada's inhaled AAT meets in U.S. Phase II

Kamada Ltd. (Tel Aviv:KMDA; NASDAQ:KMDA) advanced $0.36 to $4.89 on NASDAQ on Tuesday after its inhaled alpha-1 antitrypsin ( AAT ; A1AT ; SERPINA1 ) met the primary endpoint in a 36-patient U.S. Phase II...
07:00 , Oct 12, 2015 |  BioCentury  |  Regulation

Learning in liver

Jennifer Rhodes, Staff Writer   Patients and caregivers at FDA's patient-focused drug development meeting on alpha-1 antitrypsin deficiency are desperate for treatments for liver-affected patients, whose only option is a transplant. With two RNAi programs...
07:00 , Sep 14, 2015 |  BC Week In Review  |  Company News

ProAxsis sales and marketing update

ProAxsis launched ProteaseTag immunoassay kits to detect neutrophil elastase , which the company said is a biomarker of disease activity in cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD). In 2013, ProAxsis spun out...
07:00 , Jul 30, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Interleukin-1 (IL-1) β; neutrophil elastase (ELANE; NE; HLE)

Cardiovascular disease INDICATION: Atherosclerosis Cell culture and mouse studies suggest neutrophil extracellular trap (NET) inhibitors could help treat atherosclerosis by decreasing production of IL-1β. In human neutrophils, cholesterol increased NET formation and a small molecule...